For the quarter ending 2025-09-30, JBIO has $202,450K in assets. $23,104K in debts. $50,106K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 50,106 | 220,942 | ||
| Investments | 148,799 | - | ||
| Prepaid expenses and other current assets | 2,455 | 2,042 | ||
| Total current assets | 201,360 | 222,984 | ||
| Property and equipment, net | 176 | 147 | ||
| Operating lease right-of-use asset | 740 | 777 | ||
| Other assets | 174 | 60 | ||
| Total assets | 202,450 | 223,968 | ||
| Accounts payable | 1,350 | 7,586 | ||
| Accrued expenses and other current liabilities | 14,012 | 8,091 | ||
| Related party accrued expenses and other current liabilities | 2,048 | 2,380 | ||
| Warrant liability, related party | 4,947 | 3,563 | ||
| Total current liabilities | 22,357 | 21,620 | ||
| Convertible notes payable | 0 | - | ||
| Long-term lease liability | 747 | 792 | ||
| Total liabilities | 23,104 | 22,412 | ||
| Series a non-voting convertible preferred stock, 0.0001 par value 12,622 and no shares authorized as of september 30, 2025 and december 31, 2024, respectively 12,622 shares and no shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively-Series ANon Voting Convertible Preferred Stock | 2 | - | ||
| Common stock, 0.0001 par value 300,000,000 and 40,000,000 shares authorized as of september 30, 2025 and december 31, 2024, respectively 32,626,730 and 3,672,794 shares issued and outstanding as of september30, 2025 and december 31, 2024, respectively | 3 | 3 | ||
| Additional paid-in capital | 321,769 | 318,857 | ||
| Accumulated other comprehensive income | 29 | -24 | ||
| Accumulated deficit | -142,457 | -117,282 | ||
| Total stockholders' equity (deficit) | 179,346 | 201,556 | ||
| Total liabilities, series seed convertible preferred stock and stockholders' equity (deficit) | 202,450 | 223,968 | ||
Jade Biosciences, Inc. (JBIO)
Jade Biosciences, Inc. (JBIO)